
GLP-1 and Semaglutide Side Effects: A Week-by-Week Guide
- Jump to a Section:
The most common complaint from people starting GLP-1 treatment is nausea. The second-most common complaint is that no one explained why it happens.
Almost every common side effect of GLP-1 treatment (the class that includes treatments people often search for by names like Ozempic and semaglutide) has a direct cause rooted in how this class of treatment works in the body. For most people, these effects ease within the first 4 to 8 weeks as the body adjusts.
A note before we start: This is general health information, not medical advice. GLP-1 treatment is prescription-only in Canada, requires assessment by a licensed healthcare provider, and is not suitable for everyone. The timelines below are typical patterns, not promises. Your own experience may differ, and your prescriber should guide your plan.
Why side effects happen at all
GLP-1 treatment acts on receptors in the gut and brain. A key effect is slowing how fast the stomach empties. That change in digestion is the root of most of the side effects in the early weeks.
When food sits in your stomach longer, stretch receptors signal fullness sooner. The treatment also acts on a part of the brainstem called the area postrema, a region involved in nausea. A review in Frontiers in Endocrinology describes both pathways — slowed gastric emptying and direct brainstem signalling — as the main drivers of nausea and vomiting caused by this class of treatment.
The reassuring part: the same review notes that the brain and gut adapt over time. That is why these effects usually fade after the first several weeks.
Phase 1: The starter period (roughly weeks 1 to 4)
Doses in this class almost always begin at a low starting level. This is not the level considered therapeutic by the manufacturer — it is an adjustment period, giving your body time to get used to receptor activation before any increase.
This is the phase where side effects are most noticeable, and typically passes within 4 weeks
Nausea
This is the most commonly reported early effect. In the STEP 1 trial, nausea was the most frequently reported GI symptom — and importantly, the trial also found these effects were "typically transient and mild-to-moderate in severity and subsided with time" (Wilding et al., NEJM, 2021). Most people move through it.
A clinical review in Nutrients found that nausea prevalence is highest during the first 4 to 5 weeks, when the effect on gastric emptying is most pronounced, and that individual episodes typically last 8 days or less before resolving (Martín-Fernández de Basoa et al., Nutrients, 2023).
Why it happens: Your stomach empties more slowly, so food sits longer and fullness signals fire earlier. The treatment also activates the brainstem's nausea pathways directly.
What helps:
- Eat smaller portions more frequently
- Go easy on high-fat meals, which slow stomach emptying further
- Don't lie down right after eating
- Sip water through the day rather than drinking large amounts at once
Fatigue
Tiredness is less talked about but common in the early weeks. Part of it is simply eating less — reduced food intake means a temporary energy gap the body needs time to adjust to. Part of it may be that blood sugar is steadier than before; if you were used to energy spikes after large meals, their absence can feel different at first. The StatPearls clinical reference on semaglutide notes that these metabolic shifts during the adjustment phase can contribute to fatigue (StatPearls, NCBI Bookshelf). For most people this settles within the first few weeks.
Constipation
When the gut slows down, so does the movement of food through it. Less food moving more slowly can mean constipation. A 2025 meta-analysis found GLP-1s were associated with roughly double the rate of constipation compared with placebo, confirming it is one of the more persistent gut-related effects (Abdelsalam et al., International Journal of Obesity, 2025). A pooled analysis of the STEP trials found the median duration of constipation was 47 days, compared with 8 days for nausea — so this one can linger longer, even after nausea has passed (Wharton et al., Diabetes, Obesity and Metabolism, 2022).
What helps:
- Drink more water through the day
- Add fibre to your meals
- Take a short walk after eating
Phase 2: The first increase (roughly weeks 5 to 8)
Once your body has adjusted to the starting dose, your prescriber will likely increase the dose. , Gut side effects often tick up briefly with each increase, then settle again within a week or two. This is the same adjustment process repeating at a higher level — not a sign that something has gone wrong.
A pooled analysis of the STEP 1–3 data showed that GI side effect prevalence peaked around week 20 (roughly 4 weeks after reaching the full maintenance level) and declined steadily from there (Wharton et al., Diabetes, Obesity and Metabolism, 2022).
This is also the phase when many people first notice a clear shift in how much they want to eat. People often describe leaving food on the plate or simply feeling satisfied sooner. If eating becomes genuinely difficult or uncomfortable, that is worth raising with your prescriber.
Phase 3: Finding a steady rhythm (roughly weeks 9 to 16 and beyond)
For most people, the early gut side effects have largely faded by around week 8 to 10. The pattern reported consistently across trials and clinical reviews is that these effects show up during the start and step-up periods, then ease as the body adapts (Frontiers in Endocrinology).
Energy often improves compared with the early weeks as the body settles into a steadier metabolic rhythm.
One effect that can show up at any stage is a mild skin reaction at the injection site — a little redness or itching that usually fades within hours. In clinical trials, injection site reactions were reported in about 1.4% of participants on the active treatment versus 1.0% on placebo, and the vast majority were mild to moderate (FDA prescribing information, 2023). Rotating where you inject from week to week helps reduce build-up of irritation in one spot.
Signals that are worth a call to your provider
The following are uncommon — most people completing their first 12 weeks never experience them. They are worth knowing not to cause alarm, but so you recognize them promptly if they do occur and know to contact your healthcare provider rather than waiting it out:
- Severe, persistent abdominal pain, especially pain that radiates to the back
- Vomiting that prevents you from keeping fluids down over an extended period
- A notably rapid heartbeat at rest
- Sudden changes in vision (more relevant for people with existing eye conditions)
- Signs of an allergic reaction such as rash, swelling, or difficulty breathing
Ongoing follow-up with a licensed healthcare provider is critical. Your provider knows your baseline and can distinguish between an expected adjustment effect and something that needs attention.
Practical tips grounded in the mechanism
These aren't generic wellness tips — each one connects back to how this class of treatment actually works:
- Eat before you inject, not after. Having some food in your stomach before injecting can soften the gastric-slowing effect when it is at its strongest.
- Put protein first at meals. Protein keeps you full on fewer calories. With food intake already reduced, every bite counts.
- Go easy on alcohol in the first few weeks. Alcohol irritates the stomach lining and can compound the nausea from slowed emptying.
- Don't skip the starting dose. That low starting level exists specifically to ease you in. Clinical guidance consistently recommends a gradual step-by-step increase to reduce gut side effects (Frontiers in Endocrinology).
FAQs
How long does nausea last on this kind of treatment?
For most people, nausea is most noticeable in the first couple of weeks and then improves as the body adapts. In the STEP 1 trial, gut side effects were generally described as transient and resolved with time (Wilding et al., NEJM, 2021).
When do side effects get better?
The common pattern is improvement across the first 4 to 8 weeks. Gut effects tend to flare briefly after each step-up in level, then settle again within a week or two. A pooled analysis of the STEP 1–3 trials found that nausea, diarrhoea, and vomiting prevalence peaked around week 20 and declined steadily thereafter (Wharton et al., Diabetes, Obesity and Metabolism, 2022).
Why do I feel side effects again after a level increase?
Each increase asks your body to adapt to a higher level of receptor activation. That brief return of nausea or other gut effects is the same adjustment process repeating, and it usually eases the same way it did the first time. The STEP 5 two-year trial confirmed this pattern: gastrointestinal side effects were most common during dose escalation and infrequently led to treatment discontinuation (Garvey et al., Nature Medicine, 2022).
Are the side effects dangerous?
Most are mild to moderate and fade with time. The signals listed above call for prompt medical attention, but they are uncommon. A licensed healthcare provider should monitor your treatment throughout.
Does everyone get side effects?
No. Side effects are common but not universal, and they vary considerably from person to person. This is one reason an individual assessment with a licensed healthcare provider matters before starting.
Medically reviewed by

References
- Frontiers in Endocrinology. Mechanisms and management of GLP-1 receptor agonist-induced gastrointestinal side effects. Front Endocrinol. 2026. doi:10.3389/fendo.2026.1788698. Available from: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2026.1788698/full
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. Available from: https://cci-cic.org/wp-content/uploads/2021/04/STEP-1-Trial.pdf
- Martín-Fernández de Basoa C, et al. Gastrointestinal adverse effects of GLP-1 receptor agonists and strategies for their management. Nutrients. 2023;15(1):186. doi:10.3390/nu15010186. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes Obes Metab. 2022;24(6):1065-1077. doi:10.1111/dom.14685. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9293236
- Abdelsalam A, et al. Gastrointestinal adverse effects of GLP-1 receptor agonists: a systematic review and meta-analysis. Int J Obes. 2025. doi:10.1038/s41366-025-01859-6. Available from: https://www.nature.com/articles/s41366-025-01859-6
- Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083-2091. doi:10.1038/s41591-022-02026-4. Available from: https://www.nature.com/articles/s41591-022-02026-4
- Nuffer W, Trujillo JM. Semaglutide. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603723
- Cleveland Clinic Consult QD. GLP-1 agonists and pancreatitis: what the evidence shows. Available from: https://consultqd.clevelandclinic.org/glp1-agonists-and-pancreatitis
- Pham TT, et al. Acute pancreatitis due to different semaglutide regimens: an updated meta-analysis. Pancreatology. 2024. doi:10.1016/j.pan.2024.03.012. Available from: https://pubmed.ncbi.nlm.nih.gov/38555109/
- Living systematic review: GLP-1 receptor agonists and pancreatitis risk. medRxiv. 2025 (preprint, pending peer review). Available from: https://www.medrxiv.org/content/10.64898/2026.03.19.26348844v1.full-text






